GRT Lawyers advises ASX listed Australian medical imaging company IMEXHS Limited (IME) on its recent finance agreement to provide capital for growth

Treasury has released the exposure draft of the Competition and Consumer (Notification of Acquisitions) Determination for consultation. This draft legislative instrument sets out critical details of the new mandatory merger clearance regime, commencing 1 January 2026, including: The ACCC has also published provisional guidance on when the long form should be used—largely based on market share and

The ASX’s Listed@ASX Compliance Update (16 May 2025) highlights critical updates for listed entities. Below is a detailed summary of key changes to Listing Rule 7.1A and rights issues during suspension. Listing Rule 7.1A: Additional 10% Placement CapacityListing Rule 7.1A enables eligible small to mid-cap entities to raise capital equivalent to 10% of their ordinary

The Australian Securities Exchange (ASX) has revised Guidance Note 1, which sets out the requirements for entities aiming to list on the exchange. Effective 30 May 2025, these updates bring notable changes that will influence early-stage companies, especially in the technology, biotechnology, and medical technology sectors. The revisions aim to enhance clarity for applicants and

After the quietest start to the IPO year since the 2020 COVID lockdowns, with only about $187 million raised so far, less than half the amount at the same time in 2024, Australia’s IPO market has been waiting for a circuit breaker. What’s different? These changes will come into effect immediately. ASIC chair Joe Long hopes the changes